Maxwell Biosciences Private Investor Meeting – Virtual

Event Details

Maxwell Biosciences Private Investor Meeting - Virtual

by CONNECTpreneur Investor Network

WEDNESDAY, January 21, 2026

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Opus8 is hosting a virtual, invitation-only virtual private investor briefing featuring Maxwell Biosciences, a clinical-stage biotechnology company advancing a first-in-class Synthetic Immune System™ platform designed to transform the treatment of infectious diseases.

This closed-door session will provide direct access to Maxwell’s leadership team and an opportunity to review the company’s Claromer™ technology, extensive scientific and government validation, lead clinical strategy, and upcoming FDA milestones, as well as a discussion of current and future financing opportunities for accredited investors.

Maxwell is entering a critical value-creation phase, supported by strong Pre-IND FDA feedback and an anticipated IND submission in 2026, positioning the company for meaningful clinical and strategic inflection points. Maxwell is uniquely positioned at the intersection of antimicrobial resistance, biodefense preparedness, and next-generation anti-infectives—areas now prioritized by governments, regulators, and strategic pharma partners worldwide.

Company Overview

Maxwell Biosciences has developed an AI-driven drug discovery platform that creates synthetic small molecules designed to mimic LL-37, the human immune system’s primary antimicrobial peptide. Unlike traditional antibiotics, Maxwell’s Claromers™ are broadly effective against nearly all tested bacterial and fungal pathogens—including drug-resistant strains and biofilms—without inducing resistance.

The platform is supported by over $65 million in non-dilutive government grants and investor financing, more than 250 peer-reviewed scientific publications, and seven U.S. military Collaborative Research and Development Agreements. Maxwell’s lead clinical program is targeting Chronic Rhinosinusitis (CRS), with Phase 1 clinical trials anticipated in 2026.

What Differentiates Angiex

First-in-Class Synthetic Immune System™ — Small molecules designed to replicate natural human immunity rather than target single pathogens
Broad-Spectrum, Resistance-Free Activity — Demonstrated efficacy against hundreds of bacterial and fungal pathogens, including drug-resistant strains and biofilms
AI-Driven Claromer™ Platform — Rapid creation of a scalable library of drug candidates across multiple infectious disease indications
Strong Government & Military Validation — DARPA-seeded platform supported by $65M+ in non-dilutive funding and active U.S. defense and public health collaborations
Compelling Regulatory & IP Profile — Encouraging FDA Pre-IND feedback, robust composition-of-matter patents, and high likelihood of Qualified Infectious Disease Product (QIDP) designation with extended market exclusivity
Massive Market Opportunity — Positioned to address a global infectious disease market projected to exceed $190B, with platform-level expansion across pharma, government stockpiling, and strategic partnerships

Event Details

Date: Wednesday, January 21, 2026
Time: 11:30am – 12:30pm EST
Location: Online via Zoom

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Skylar Rallison — srallison@opus8.com

Event Details